Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Merrimack Pharmaceuticals stock | $6.4
Learn how to easily invest in Merrimack Pharmaceuticals stock.
Merrimack Pharmaceuticals, Inc is a biotechnology business based in the US. Merrimack Pharmaceuticals shares (MACK) are listed on the NASDAQ and all prices are listed in US Dollars.
How to buy shares in Merrimack Pharmaceuticals
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – MACK – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
- MACK shares summary
- Compare share dealing platforms
- Is MACK stock a buy or sell?
- Stock performance over time
- Can I short MACK shares?
- Are MACK shares over-valued?
- Merrimack Pharmaceuticals's financials
- How volatile are MACK shares?
- Does Merrimack Pharmaceuticals pay a dividend?
- Have MACK shares ever split?
- Other common questions
Merrimack Pharmaceuticals stock price (NASDAQ: MACK)Use our graph to track the performance of MACK stocks over time.
Merrimack Pharmaceuticals shares at a glance
|Latest market close||$6.40|
|52-week range||$3.24 - $9.35|
|50-day moving average||$6.32|
|200-day moving average||$6.78|
|Wall St. target price||$4.00|
|Dividend yield||$1.497 (23.43%)|
|Earnings per share (TTM)||$0.10|
Buy Merrimack Pharmaceuticals shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Merrimack Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Merrimack Pharmaceuticals price performance over time
|1 week (2021-07-24)||N/A|
|1 month (2021-07-02)||1.59%|
|3 months (2021-05-04)||-6.43%|
|6 months (2021-01-31)||N/A|
|1 year (2020-07-31)||N/A|
|2 years (2019-07-31)||N/A|
|3 years (2018-07-31)||N/A|
|5 years (2016-07-31)||N/A|
Is Merrimack Pharmaceuticals under- or over-valued?
Valuing Merrimack Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Merrimack Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Merrimack Pharmaceuticals's PEG ratio
Merrimack Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.07. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Merrimack Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Merrimack Pharmaceuticals's EBITDA
Merrimack Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $134,000.
The EBITDA is a measure of a Merrimack Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
Merrimack Pharmaceuticals financials
|Gross profit TTM||$-9,100,000|
|Return on assets TTM||-12.65%|
|Return on equity TTM||-23.51%|
|Market capitalisation||$80.5 million|
TTM: trailing 12 months
Shorting Merrimack Pharmaceuticals shares
There are currently 349,168 Merrimack Pharmaceuticals shares held short by investors – that's known as Merrimack Pharmaceuticals's "short interest". This figure is 3.5% up from 337,446 last month.
There are a few different ways that this level of interest in shorting Merrimack Pharmaceuticals shares can be evaluated.
Merrimack Pharmaceuticals's "short interest ratio" (SIR)
Merrimack Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Merrimack Pharmaceuticals shares currently shorted divided by the average quantity of Merrimack Pharmaceuticals shares traded daily (recently around 26213.813813814). Merrimack Pharmaceuticals's SIR currently stands at 13.32. In other words for every 100,000 Merrimack Pharmaceuticals shares traded daily on the market, roughly 13320 shares are currently held short.
However Merrimack Pharmaceuticals's short interest can also be evaluated against the total number of Merrimack Pharmaceuticals shares, or, against the total number of tradable Merrimack Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Merrimack Pharmaceuticals's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Merrimack Pharmaceuticals shares in existence, roughly 30 shares are currently held short) or 0.0391% of the tradable shares (for every 100,000 tradable Merrimack Pharmaceuticals shares, roughly 39 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Merrimack Pharmaceuticals.
Find out more about how you can short Merrimack Pharmaceuticals stock.
Merrimack Pharmaceuticals share dividends
We're not expecting Merrimack Pharmaceuticals to pay a dividend over the next 12 months.
Have Merrimack Pharmaceuticals's shares ever split?
Merrimack Pharmaceuticals's shares were split on a 1271:1000 basis on 5 September 2019. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1271 shares. This wouldn't directly have changed the overall worth of your Merrimack Pharmaceuticals shares – just the quantity. However, indirectly, the new 21.3% lower share price could have impacted the market appetite for Merrimack Pharmaceuticals shares which in turn could have impacted Merrimack Pharmaceuticals's share price.
Merrimack Pharmaceuticals share price volatility
Over the last 12 months, Merrimack Pharmaceuticals's shares have ranged in value from as little as $3.24 up to $9.35. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Merrimack Pharmaceuticals's is 2.284. This would suggest that Merrimack Pharmaceuticals's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Merrimack Pharmaceuticals overview
Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was founded in 1993 and is headquartered in Cambridge, Massachusetts. .
Stocks similar to Merrimack Pharmaceuticals
Merrimack Pharmaceuticals in the news
Frequently asked questionsWhat percentage of Merrimack Pharmaceuticals is owned by insiders or institutions?
Currently 0.352% of Merrimack Pharmaceuticals shares are held by insiders and 64.546% by institutions. When does the fiscal year end for Merrimack Pharmaceuticals?
Merrimack Pharmaceuticals's fiscal year ends in December. Where is Merrimack Pharmaceuticals based?
Merrimack Pharmaceuticals's address is: One Broadway, Cambridge, MA, United States, 02142 What is Merrimack Pharmaceuticals's ISIN number?
Merrimack Pharmaceuticals's international securities identification number is: US5903282094 What is Merrimack Pharmaceuticals's CUSIP number?
Merrimack Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 590328100
More guides on Finder
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
How to buy DoubleDown Interactive (DDI) stock when it goes public
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
How to buy Omniq Corp (OMQS) stock when it goes public
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
How to buy Mechanical Technology (MKTYP) stock when it goes public
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
Ask an Expert